Name: Telomir Pharmaceuticals, Inc. (TELO) Cash Flow Statement
Creator: FinSpry

Telomir Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Telomir Pharmaceuticals, Inc. (TELO) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Operating Activities
Net Income	-16.53	-13.07	-0.85	-0.14
Depreciation & Amortization	4.34	0.00	0.00	0.00
Stock Based Compensation	6.87	0.00	0.00	0.00
Change in Working Capital	0.13	0.11	0.39	0.02
Change in Accounts Payable	0.18	0.11	0.39	0.02
Change in Other Working Capital	-0.06	1.61	0.00	0.00
Other Operating Activities	0.13	1.61	0.00	0.00
Net Cash from Operating Activities	-5.07	-3.86	-0.47	-0.12
Investing Activities
Net Cash from Investing Activities	0.00	0.00	0.00	0.00
Financing Activities
Debt Repayment	-0.10	0.00	0.00	0.00
Common Stock Issued	6.83	1.00	0.06	0.00
Other Financing Activities	-0.40	1.41	-0.05	0.12
Net Cash from Financing Activities	6.34	3.86	0.47	0.12
Summary
Net Change in Cash	1.26	0.00	0.00	0.00
Cash at Beginning of Period	0.00	0.00	0.00	0.00
Cash at End of Period	1.27	0.00	0.00	0.00
Free Cash Flow	-5.07	-3.86	-0.47	-0.12